Tracking a Silent Killer: New Biomarker Identified for Arrhythmogenic Cardiomyopathy (1 of 1) (IMAGE)

American Association for the Advancement of Science (AAAS)

Tracking a Silent Killer: New Biomarker Identified for Arrhythmogenic Cardiomyopathy (1 of 1)

Caption

Tissue from a heart of a patient with arrhythmogenic cardiomyopathy. This material relates to a paper that appeared in the Feb. 12, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by J.-P. Song at Fuwai Hospital in Beijing, China; and colleagues was titled, " Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy."

Credit

J.-P. Song <i>et al., Science Translational Medicine</i> (2020)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.